Johnson & Johnson

FDA approves Steqeyma (ustekinumab-stba), a biosimilar to Stelara, for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults and pediatric patients. Steqeyma demonstrated high similarity to its reference product in terms of safety and efficacy.

Digital transformation in pharma is crucial, with 75% of organizations implementing Pharma 4.0. Key drivers include patient demands, regulatory changes, and competition. Top technologies include AI, IoT, blockchain, and digital twins. Strategic insights focus on R&D, supply chain, marketing, and patient engagement.

GSK announced that ViiV Healthcare, with Pfizer and Shionogi as shareholders, received a positive CHMP opinion for Vocabria in combination with J&J's Rekambys for treating HIV-1 in adolescents.

The global Epidermal Growth Factors (EGFs) market was valued at US$ 1.1 Bn in 2023 and is expected to grow at a CAGR of 11.3% to reach US$ 3.7 Bn by 2034, driven by applications in wound healing, cancer therapies, skincare, and regenerative medicine. Key drivers include rising demand for anti-aging products, advancements in biopharmaceutical research, increasing prevalence of chronic diseases, and strategic investments by companies like Thermo Fisher Scientific and Johnson & Johnson.

The European Commission granted marketing authorisation for Imuldosa®, a biosimilar to Stelara®, indicated for immune-mediated inflammatory diseases. The approval follows a positive CHMP opinion based on comprehensive similarity data, paving the way for its launch in the EU ustekinumab market.

Biocon Biologics Ltd announced CHMP's positive opinion recommending approval of YESINTEK, an Ustekinumab biosimilar for treating plaque psoriasis, psoriatic arthritis, and Crohn’s disease. Clinical studies showed similar pharmacokinetic, safety, efficacy, and immunogenicity profiles compared to the originator product. The CHMP opinion follows U.S. FDA approval earlier this month. Biocon Biologics had previously entered a licensing agreement with Janssen for commercializing YESINTEK in the U.S.

The global Acute Myeloid Leukemia Therapeutics Market is projected to grow at a CAGR of 13.4% during 2024-2032, driven by advances in targeted therapies and immunotherapies.

Johnson & Johnson aims to cure half of all multiple myeloma patients, shifting from disease management to potential cure. Their therapies, including Darzalex and Carvykti, have shown significant improvements in progression-free survival and response rates, with innovative approaches like bispecific antibodies and precision medicine. The company emphasizes early use of effective treatments to reduce healthcare burden.

Protagonist Therapeutics, with strong financial health and a 95% return over the past year, is advancing its lead candidate, rusfertide, in Phase 3 trials for polycythemia vera. Strategic partnerships with Johnson & Johnson and Takeda support pipeline growth. The company's robust cash position sustains operations through 2027, with a diverse pipeline including PN-881 for psoriasis. Key clinical trial outcomes will significantly impact its market position and growth potential.